Name: Labetuzumab govitecan
Brand: TargetMol
SKU: T25593
Rating: 4.5 (1 reviews)

规格

价格

库存

数量

1 mg

¥ 6,230

2-4周

5 mg

¥ 15,600

2-4周

生物活性

产品描述	Labetuzumab govitecan is an antibody-drug conjugate (ADC) targeting CEACAM5, composed of the labetuzumab antibody, the payload SN-38, and a pH-sensitive linker. It can be used in research on malignant tumors such as colorectal cancer.
体内活性	Labetuzumab govitecan 以总量 1.0 mg 腹腔注射给药，可延长 GW-39 肺转移小鼠模型的中位生存期。 Labetuzumab govitecan 按 25 mg/kg 剂量腹腔注射，每周给药 2 次、连续给药 4 周，可延长 LS174T 皮下异种移植裸鼠模型的中位生存期 [2]。
别名	Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38, hMN-14-SN-38
反应种属	Human
应用	ELISA FCM Functional assay
抗体种类	Monoclonal, ADC
缓冲液	Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
内毒素	<1.0 EU/mg

抗体信息

同型

IgG1

偶联与修饰

偶联

SN38

抗原信息

化学信息

CAS No.	1469876-18-3
密度	no data available

储存&溶解度

存储	Store at -20°C Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准

Labetuzumab govitecan